Literature DB >> 3891302

Diltiazem. A review of its pharmacological properties and therapeutic efficacy.

M Chaffman, R N Brogden.   

Abstract

Diltiazem is an orally and intravenously active calcium channel blocking agent shown to be an effective and well-tolerated treatment for stable angina and angina due to coronary artery spasm. Its efficacy in these diseases has generally been similar to that of nifedipine or verapamil - alternative calcium channel blockers with which diltiazem has many electrophysiological, haemodynamic, and antiarrhythmic similarities. The antianginal mechanism of diltiazem cannot be precisely described; however, it appears to increase myocardial oxygen supply and decrease myocardial oxygen demand, mainly by coronary artery dilatation and/or via both direct and indirect haemodynamic alterations. Diltiazem has also shown substantial efficacy in the treatment of unstable angina, hypertension, and supraventricular tachyarrhythmias, but further study is necessary before its place in the treatment of these diseases may be clearly established. Although headache due to peripheral vasodilatation and depression of atrioventricular nodal conduction may be troublesome, side effects occur in only 2 to 10% of patients receiving diltiazem and are generally minor in nature. Thus, diltiazem offers a worthwhile alternative to other agents currently available for the treatment of angina pectoris. Although the infrequency of serious side effects may offer an advantage, its relative place in therapy compared with that of other calcium channel blockers remains to be clarified.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3891302     DOI: 10.2165/00003495-198529050-00001

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  311 in total

1.  Effects of calcium-antagonistic coronary vasodilators on myocardial contractility and membrane potentials.

Authors:  H Nabata
Journal:  Jpn J Pharmacol       Date:  1977-04

2.  Effects of agents which inhibit the slow channel on sinus node automaticity and atrioventricular conduction in the dog.

Authors:  D P Zipes; J C Fischer
Journal:  Circ Res       Date:  1974-02       Impact factor: 17.367

3.  Effects of calcium antagonists on coronary spasm and pulmonary artery contraction in comparison to their antagonistic action against K-strophanthin in isolated guinea pig atria.

Authors:  E Lindner; D Ruppert
Journal:  Pharmacology       Date:  1982       Impact factor: 2.547

Review 4.  Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem.

Authors:  P D Henry
Journal:  Am J Cardiol       Date:  1980-12-01       Impact factor: 2.778

5.  Effect of diltiazem on left ventricular isovolumic relaxation time in patients with hypertrophic cardiomyopathy.

Authors:  M Nagao; S Omote; A Takizawa; H Yasue
Journal:  Jpn Circ J       Date:  1983-01

6.  Effect of calcium antagonists on leukotriene D4-induced contractions of the guinea-pig trachea and lung parenchyma.

Authors:  B M Weichman; R M Muccitelli; S S Tucker; M A Wasserman
Journal:  J Pharmacol Exp Ther       Date:  1983-05       Impact factor: 4.030

7.  Pharmacokinetics and metabolism of diltiazem in man.

Authors:  V Rovei; R Gomeni; M Mitchard; J Larribaud; C Blatrix; J J Thebault; P L Morselli
Journal:  Acta Cardiol       Date:  1980       Impact factor: 1.718

8.  Beneficial effects of diltiazem in coronary artery disease.

Authors:  J Kenny; K Daly; G Bergman; S Kerkez; D E Jewitt
Journal:  Br Heart J       Date:  1984-07

9.  Effects of diltiazem on conduction of premature impulses during acute myocardial ischemia and reperfusion.

Authors:  T Fujimoto; T Peter; H Hamamoto; W J Mandel
Journal:  Am J Cardiol       Date:  1981-11       Impact factor: 2.778

10.  Differential effects of systemic and intracoronary calcium channel blocking agents on global and regional left ventricular function in conscious dogs.

Authors:  R A Walsh; F R Badke; R A O'Rourke
Journal:  Am Heart J       Date:  1981-09       Impact factor: 4.749

View more
  52 in total

Review 1.  Gamma scintigraphy in the evaluation of pharmaceutical dosage forms.

Authors:  S S Davis; J G Hardy; S P Newman; I R Wilding
Journal:  Eur J Nucl Med       Date:  1992

2.  Mechanism of action of clentiazem on human coronary artery and myocardium.

Authors:  H Narita; P H Zera; R Ginsburg
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

3.  Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity in vivo without altering the expression of intestinal mRNA or protein.

Authors:  A G Pinto; J Horlander; N Chalasani; M Hamman; A Asghar; D Kolwankar; S D Hall
Journal:  Br J Clin Pharmacol       Date:  2005-04       Impact factor: 4.335

4.  A comparison of diltiazem and metoprolol in hypertension. Swedish Diltiazem-Metoprolol Multicentre Study Group.

Authors:  T Hedner; T Thulin; S Gustafsson; S O Olsson
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 5.  Calcium antagonists in patients with heart failure. A review.

Authors:  H Reicher-Reiss; E Barasch
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 6.  Diltiazem. A reappraisal of its pharmacological properties and therapeutic use.

Authors:  M M Buckley; S M Grant; K L Goa; D McTavish; E M Sorkin
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

Review 7.  Guide to drug dosage in renal failure.

Authors:  W M Bennett
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

8.  Prediction of drug distribution into human milk from physicochemical characteristics.

Authors:  H C Atkinson; E J Begg
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

9.  Pharmacokinetics and metabolism of diltiazem in rabbits after a single intravenous or single oral administration.

Authors:  P K Yeung; S J Mosher; P T Pollak
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Jan-Mar       Impact factor: 2.441

Review 10.  Nitrendipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension.

Authors:  K L Goa; E M Sorkin
Journal:  Drugs       Date:  1987-02       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.